"Bavarian Nordic shares sink by 12% after mpox sales slump in Q3" was originally created and published by Pharmaceutical ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 ...

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.

Its Spikevax COVID vaccine brought in sales of $1.8 billion ... as well as a substantial amount of inventory with customers already." Sales of Spikevax outside the U.S. were lower than for ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...